Health and Human Services Department, Food and Drug Administration
The Food and Drug Administration (FDA, the Agency, or we) is announcing a public hearing on the potential future therapeutic use of psychedelic drugs. In collaboration with federal partners, FDA is holding this public hearing to obtain feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings.
Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2026-N-7542] AGENCY: Food and Drug Administration, HHS. ACTION: Public hearing; request for comments. SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is announcing a public hearing on the potential future therapeutic use of psychedelic drugs. In collaboration with federal partners, FDA is holding this public hearing to obtain feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings. DATES: The public hearing will be held with an in-person and virtual option ( i.e., hybrid) on September 14, 2026, from 12:30 p.m. to 4:30 p.m. Eastern Time. Registration, including requests to present at the public hearing, must be completed through the meeting registration page at www.fda.gov/​news-events/​fda-meetings-conferences-and-workshops/​considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026 by 11:59 p.m. Eastern Time on August 21, 2026. Questions about registration and participation should be sent to PsychedelicsHearing@fda.hhs.gov and should include the title of this notice. See the SUPPLEMENTARY INFORMATION section for attendance and registration information. Comments may be submitted at any time until October 5, 2026. Comments received after that date will not be considered. See the ADDRESSES section for …
Citation: 91 FR 43095
